一种分子印迹固相萃取技术-电位法联用检测有机污染物的方法

本发明涉及检测有机污染物的方法，具体地说是一种分子印迹固相萃取技术-电位法联用检测有机污染物的方法。采用有机污染物分子印迹聚合物作为固相萃取填料对样品中有机污染物进行富集分离，而后利用有机污染物分子印迹聚合物膜离子选择性电极对上述富集后的有机污染物进行电位检测，从而实现复杂样品中有机污染物的电位检测。本发明采用分子印迹固相萃取技术消除影响电位检测的复杂样品基体效应，有效提高了电位检测的精确度，扩大了电位检测法的应用范围

A molecular engram solid phase extraction technology-potential method of organic pollutants combined detection method

本发明涉及检测有机污染物的方法，具体地说是一种分子印迹固相萃取技术 电位法联用检测有机污染物的方法。采用有机污染物分子印迹聚合物作为固相萃取填料对样品中有机污染物进行富集分离，而后利用有机污染物分子印迹聚合物膜离子选择性电极对上述富集后的有机污染物进行电位检测，从而实现复杂样品中有机污染物的电位检测。本发明采用分子印迹固相萃取技术消除影响电位检测的复杂样品基体效应，有效提高了电位检测的精确度，扩大了电位检测法的应用范围

pn结及其制备方法

本发明公开了一种pn结及其制备方法，该pn结包括n型Si半导体层和位于所述n型Si半导体层中部区域的p型SnO半导体层，其中，所述n型Si半导体层上设置有第一电极；所述p型SnO半导体层上设置有第二电极。本发明的pn结有明显的整流效应，可应用于发光二极管、太阳能电池、光电探测器、气敏传感器等半导体器件，扩大了氧化亚锡的应用范围

一种氮化锌锡pn结及其制备方法

本发明公开了一种氮化锌锡pn结及其制备方法，该pn结包括紧密接触的p型半导体和n型半导体，以及分别设于所述p型半导体和n型半导体上的第一电极和第二电极，其特征在于，所述的p型半导体的材料为Si，所述的n型半导体的材料为ZnSnN2。本发明的pn结有明显的整流效应，在太阳能电池领域具有潜在的应用价值

Effects of soil surface mulching on the growth and physiological characteristics of grafted and non-grafted cucumbers in solar greenhouse.

研究了地表覆盖秸秆、地膜和秸秆加膜对日光温室嫁接和非嫁接黄瓜生长与生理特性的影响.结果表明,地表覆盖可有效促进植株生长,嫁接黄瓜覆盖秸秆加膜、地膜与秸秆的株高和茎粗依次比对照增加91、71、57cm和0·127、0·086、0·111cm,非嫁接黄瓜增幅较小;地表覆盖可增强光合作用,嫁接黄瓜覆盖秸秆加膜、地膜、秸秆的净光合速率分别比对照增加2·63、2·08与1·36μmol·m-2·s-1,非嫁接黄瓜增幅较小;嫁接黄瓜覆盖秸秆加膜和秸秆的叶绿素含量比对照增加1·8%和3·15%,而覆盖地膜的叶绿素含量降低了3·8%,非嫁接黄瓜的叶绿素含量变幅较小;嫁接黄瓜覆盖秸秆加膜、地膜、秸秆的根系活力比对照提高0·98、0·48和0·8mgTTC·g-1FW,同一处理的非嫁接黄瓜根系活力增幅较小;地表覆盖可增加单株干物重,提高早期产量和总产量,嫁接黄瓜覆盖秸秆加膜、地膜与秸秆的单株产量比非嫁接黄瓜分别增加16%、5·3%和3·4%

Molecular Cloning and Characterization of a Putative Promoter Region of mPC-1 Gene Homologous to hPC-1

为了鉴定鼠mPC-1基因表达的调控元件,克隆并分析了该基因的启动子.构建了一系列mPC-1基因启动子的截短序列.通过荧光素酶报道基因,分析了它们在前列腺癌细胞和其它细胞中的表达.结果表明,在AR阳性细胞系中,mPC-1基因启动子活性远远高于SV40和p61-PSA启动子,mPC-1基因启动子599bp至449bp可能含有一个负调控元件;mPC-11.1kb启动子控制的表达主要在前列腺癌细胞系中;雄激素可调控mPC-11.1kb启动子表达.mPC-11.1kb序列是一个有前列腺癌细胞特异性和较强的启动子,经过进一步的修饰有可能作为一种有用的前列腺癌基因治疗元件.To identify the regulatory region that are responsible for the expression of mPC-1,we have isolated and characterized the mPC-1 gene promoter.Sequence analysis of the mPC-1 5'-flanking region and a series of truncated constructs were performed,which were transiently transfected into the prostate cancer cell lines and non-prostate cancer cell lines and analyzed through Dual-luciferase reporter assay system.The relative activity of mPC-1 gene promoter was by far higher than pGL3-control containing SV40 promoter and enhancer and p61-PSA containing hPSA 6 kb promoter in AR(androgen receptor,AR)-positive prostate cancer cell lines.The region from 599 bp to 449 bp of mPC-1 promoter might contain a negative regulatory element.The expression of mPC-1 1.1 kb fragment is mainly restricted into prostate cancer cell lines.The relative activity of mPC-1 1.1 kb 5'-flanking region was regulated by androgen.The results demonstrated that the 1.1 kb fragment of mPC-1 5'-flanking region was relatively strong and prostate cancer cell specific promoter region.The 1.1 kb promoter of mPC-1 gene might be well suited to prostate cancer gene therapy if the promoter was properly modified.国家高技术研究发展计划(863计划)(No.2002AA223061);; 国家自然科学基金(No.30070296)资助~

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials